Daniel Rea

10.8k citations

126 papers · 4.3k indexed · h-index 32

Impact in

Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Global Cancer Incidence and Screening

Papers in ⓘ

Cancer Research 77
- Breast Cancer Treatment Studies 67
- Cancer Genomics and Diagnostics 16
Oncology 69
- HER2/EGFR in Cancer Research 34
- Cancer Treatment and Pharmacology 27
- Global Cancer Incidence and Screening 9

Co-authors: John M.S. Bartlett (45 shared papers)Christos Markopoulos (33 shared papers)Caroline Seynaeve (30 shared papers)Annette Hasenburg (32 shared papers)Lucinda Billingham (7 shared papers)Cornelis J.�H. van de Velde (26 shared papers)Hein Putter (17 shared papers)Christopher Poole (13 shared papers)
Journals: Journal of Clinical Oncology (33 papers)Cancer Research (13 papers)Annals of Oncology (7 papers)British Journal of Cancer (7 papers)European Journal of Cancer (5 papers)
Partner nations: United Kingdom Canada Netherlands

In The Last Decade

Daniel Rea

120 papers receiving 4.2k citations

Peers

Countries citing papers authored by Daniel Rea

Since Specialization

Citations

This map shows the geographic impact of Daniel Rea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Rea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Rea more than expected).

Fields of papers citing papers by Daniel Rea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Rea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Rea. The network helps show where Daniel Rea may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel Rea, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel Rea Line = papers co-authored together Daniel Rea links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 126 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors Journal of Clinical Oncology ·Anne O’Donnell, Sandrine Faivre, Howard A. Burris, Daniel Rea, Vassiliki A. Papadimitrakopoulou, N. Shand, Heidi A. Lane, Katharine Hazell, Ulrike Zoellner, John M. Kovarik, Cathryn Brock, Suzanne F. Jones, Éric Raymond, Ian Judson	2008	371
2	aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. Journal of Clinical Oncology ·Richard Gray, Daniel Rea, Kelly Handley, S. Bowden, Philip Perry, Helena Earl, Christopher Poole, T Bates, Shan Chetiyawardana, John Dewar, Indrajit Fernando, Robert Grieve, J. J. Nicoll, Zenor Rayter, A. Robinson, Asad Salman, John Yarnold, Sarah Bathers, Andrea Marshall, Martin Lee, (unknown)	2013	290
3	Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas New England Journal of Medicine ·Michael Cullen, Neil Steven, Lucinda Billingham, Claire Gaunt, Mark Hastings, Peter Simmonds, Nicholas Stuart, Daniel Rea, Mark Bower, Indrajit Fernando, Robert Huddart, Simon Gollins, Andrew Stanley	2005	275
4	Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial The Lancet ·Cornelis JH van de Velde, Daniel Rea, Caroline Seynaeve, Hein Putter, Annette Hasenburg, Jean-Michel Vannetzel, Robert Paridaens, Christos Markopoulos, Yasuo Hozumi, E.T.M. Hille, D. G. Kieback, Lina Asmar, Jan Smeets, J.W.R. Nortier, Peyman Hadji, John M.S. Bartlett, Stephen E. Jones	2011	264
5	Ductal carcinoma in situ: to treat or not to treat, that is the question British Journal of Cancer ·(unknown), Maartje van Seijen, Esther H. Lips, Alastair M. Thompson, Serena Nik‐Zainal, P. Andrew Futreal, E. Shelley Hwang, Ellen Verschuur, Joanna Lane, Jos Jonkers, Daniel Rea, Jelle Wesseling	2019	191
6	Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer British Journal of Cancer ·Syed A. Hussain, Raji Ganesan, Gary Reynolds, Ludwig Gross, A.R. Stevens, Jaromı́r Pastorek, Philip I. Murray, Branko Perunović, M. S. Anwar, Lucinda Billingham, Nicholas D. James, D. Spooner, Christopher Poole, Daniel Rea, Daniel H. Palmer	2007	166
7	Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer JAMA ·W. van de Water, Christos Markopoulos, Cornelis J.�H. van de Velde, Caroline Seynaeve, Annette Hasenburg, Daniel Rea, Hein Putter, J.W.R. Nortier, Anton J.M. de Craen, E.T.M. Hille, Esther Bastiaannet, Peyman Hadji, Rudi G. J. Westendorp, Gerrit‐Jan Liefers, Stephen E. Jones	2012	164
8	Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor Induction In Vivo JNCI Journal of the National Cancer Institute ·P. A. Philip, Daniel Rea, P. Thavasu, J. Carmichael, N Stuart, Helaine Rockett, Dennis Talbot, Trivadi S. Ganesan, George R. Pettit, Frances R. Balkwill, Adrian L. Harris	1993	151
9	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others JNCI Journal of the National Cancer Institute ·John M.S. Bartlett, Jane Bayani, Andrea Marshall, Janet Dunn, Amy M. Campbell, Carrie Cunningham, Monika Sobol, Peter Hall, Christopher Poole, David Cameron, Helena Earl, Daniel Rea, Iain R. Macpherson, Peter Canney, Adele Francis, Christopher McCabe, Sarah E. Pinder, Luke Hughes‐Davies, Andreas Makris, Robert C. Stein, (unknown)	2016	148
10	Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial Journal of Clinical Oncology ·John M.S. Bartlett, Cassandra Brookes, Tammy Robson, Cornelis J.�H. van de Velde, Lucinda Billingham, Fiona Campbell, Margaret Grant, Annette Hasenburg, E.T.M. Hille, Charlene Kay, D. G. Kieback, Hein Putter, Christos Markopoulos, Elma Meershoek‐Klein Kranenbarg, Elizabeth A. Mallon, Luc Dirix, Caroline Seynaeve, Daniel Rea	2011	142
11	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer British Journal of Cancer ·Yvette Drew, Jonathan A. Ledermann, Geoff Hall, Daniel Rea, Rosalind Glasspool, Martin Highley, Gordon C. Jayson, Julieann Sludden, J. C. Murray, David Jamieson, Sarah Halford, Gary D Acton, Zoe Backholer, Raffaella Mangano, Alan V. Boddy, Nicola J. Curtin, Ruth Plummer	2016	126
12	Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial Annals of Oncology ·John M.S. Bartlett, Dennis C. Sgroi, Kai Treuner, Y. Zhang, Ikhlaaq Ahmed, Tammy Piper, Ranelle Salunga, Elena F. Brachtel, Sarah Pirrie, Catherine A. Schnabel, Daniel Rea	2019	125
13	Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial The Lancet ·Annie Young, Lucinda Billingham, Gulnaz Begum, David Kerr, Ana Hughes, Daniel Rea, Stephen F Shepherd, Andrew Stanley, Ann T. Sweeney, Jonathan T. Wilde, Keith Wheatley	2009	107
14	Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601) The Lancet Oncology ·John M.S. Bartlett, Alison F. Munro, Janet Dunn, Christopher C. McConkey, Sarah Jordan, Chris Twelves, David Cameron, Jeremy Thomas, Fiona Campbell, Daniel Rea, Elena Provenzano, Carlos Caldas, Paul D.P. Pharoah, Louise Hiller, Helena Earl, Christopher Poole	2010	91
15	HeterogeneousHER2Gene Amplification American Journal of Clinical Pathology ·Alastair I. Bartlett, Jane Starcyznski, Tammy Robson, Alex MacLellan, Fiona Campbell, Cornelis J.�H. van de Velde, Annette Hasenburg, Christos Markopoulos, Caroline Seynaeve, Daniel Rea, John M.S. Bartlett	2011	89
16	Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study Journal of Clinical Oncology ·Vicky S. Sabine, Cheryl Crozier, Cassandra Brookes, Camilla Drake, Tammy Piper, Cornelis J.�H. van de Velde, Annette Hasenburg, D. G. Kieback, Christos Markopoulos, Luc Dirix, Caroline Seynaeve, Daniel Rea, John M.S. Bartlett	2014	86
17	What advice are oncologists and surgeons in the United Kingdom giving to breast cancer patients about physical activity? International Journal of Behavioral Nutrition and Physical Activity ·Amanda Daley, S. Bowden, Daniel Rea, Lucinda Billingham, Amtul R Carmicheal	2008	69
18	Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis Journal of Clinical Oncology ·D.B.Y. Fontein, Caroline Seynaeve, Peyman Hadji, E.T.M. Hille, W. van de Water, Hein Putter, Elma Meershoek‐Klein Kranenbarg, Annette Hasenburg, Robert Paridaens, Jean-Michel Vannetzel, Christos Markopoulos, Yasuo Hozumi, John M.S. Bartlett, Stephen E. Jones, Daniel Rea, J.W.R. Nortier, Cornelis J.�H. van de Velde	2013	57
19	aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. Journal of Clinical Oncology ·Richard Gray, Daniel Rea, Kelly Handley, S. Bowden, Philip Perry, Helena Earl, Christopher Poole, T Bates, Shan Chetiyawardana, John Dewar, Indrajit Fernando, Robert Grieve, J. J. Nicoll, Zenor Rayter, A. Robinson, Asad Salman, John Yarnold, Sarah Bathers, Andrea Marshall, Martin Lee, (unknown)	2013	50
20	Coagulopathic complications in breast cancer Cancer ·Graham J. Caine, Paul Stonelake, Daniel Rea, Gregory Y.H. Lip	2003	49

About Daniel Rea

Daniel Rea is a scholar working on Cancer Research, Oncology, Genetics, Pulmonary and Respiratory Medicine and Internal Medicine, having authored 126 papers that have together received 4.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (67 papers), Estrogen and related hormone effects (38 papers), HER2/EGFR in Cancer Research (34 papers), Advanced Breast Cancer Therapies (32 papers), Cancer Treatment and Pharmacology (27 papers), Cancer Genomics and Diagnostics (16 papers), Global Cancer Incidence and Screening (9 papers) and Breast Lesions and Carcinomas (8 papers). The work is most often cited by research in Cancer Research (1.8k citations), Oncology (2.5k citations), Genetics (999 citations), Internal Medicine (127 citations) and Pulmonary and Respiratory Medicine (971 citations). Daniel Rea has collaborated with scholars based in United Kingdom, Canada and Netherlands. Frequent co-authors include John M.S. Bartlett, Christos Markopoulos, Caroline Seynaeve, Annette Hasenburg, Lucinda Billingham, Cornelis J.�H. van de Velde, Hein Putter, Christopher Poole, S. Bowden and E.T.M. Hille. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, British Journal of Cancer and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact